Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors
The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.
1. A method of treating a skin disorder in a patient, comprising topically administering to said patient a therapeutically effective amount of a compound which is 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl}-3-oxo-propionitrile, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl}-3-oxo-propionitrile is topically administered.
3. The method of claim 1 , wherein the compound is administered in the form of a transdermal patch.
4. The method of claim 1 , wherein the compound is administered in the form of an ointment.
5. The method of claim 1 , wherein the compound is administered in the form of a lotion.
6. The method of claim 1 , wherein the compound is administered in the form of a cream.
7. The method of claim 1 , wherein the compound is administered in the form of a gel.
8. The method of claim 1 , wherein the skin disorder is selected from atopic dermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis, and allergic contact sensitization.
9. The method of claim 1 , wherein the skin disorder is atopic dermatitis.
10. The method of claim 1 , wherein the skin disorder is psoriasis.
11. The method of claim 1 , wherein the skin disorder is skin sensitization.
12. The method of claim 1 , wherein the skin disorder is skin irritation.
13. The method of claim 1 , wherein the skin disorder is skin rash.
14. The method of claim 1 , wherein the skin disorder is contact dermatitis.
15. The method of claim 1 , wherein the skin disorder is allergic contact sensitization.